3TC: the good news and the bad news. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


3TC: the good news and the bad news. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

PI Perspect. 1995 May;(no 16):4. Unique Identifier : AIDSLINE AIDS/95700457
Cheng B

Abstract: Recent European and U.S. studies comparing AZT alone or in combination with 3TC or DDC are showing the best results from a combination therapy of AZT and 3TC. Together, the studies demonstrate a clear advantage for beginning therapy with AZT plus 3TC rather than starting with AZT alone. Even people who have previously used AZT receive added benefit by switching to this combination. Data also are confirming that the AZT/3TC combination is having a longer-lasting antiviral effect than single drugs or previously-studied combinations. Unfortunately, these study findings are greatly increasing the demand for 3TC, and the sponsor can no longer meet supply needs for early access to the drug. Glaxo, the producer of 3TC, now limits enrollment conditions for the drug.
Keywords: Clinical Trials CD4 Lymphocyte Count Drug Therapy, Combination Europe Human HIV Infections/*DRUG THERAPY United States Zalcitabine/ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE/ *THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE NEWSLETTER ARTICLEKWDclinicaltrialscd4lymphocytecountdrugtherapy,combinationeuropehumanhivinfections/KWDdrugtherapyunitedstateszalcitabine/analogs&derivatives/administration&dosage/KWDtherapeuticusezidovudine/administration&dosage/therapeuticusenewsletterarticle
951230
M95C3177

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .